Stocks · News reference

Truist Securities Maintains Buy on Abivax, Raises Price Target to $155

Jul 2, 2026, 11:42 AMBenzinga Newsdesk

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaJul 30, 2026, 8:19 PMBenzinga Newsdesk
Abivax Completes Pre-New Drug Application Interaction For Obefazimod With FDA To Treat Adults With Moderately To Severely Active Ulcerative Colitis
ABVX PARIS:FR
BenzingaJul 23, 2026, 6:06 PMVandana Singh
Palisade Bio Analyst Sees Lead Drug Can Potentially Bridge Gap in Ulcerative Colitis
Analyst initiates a Buy rating on Palisade Bio with an $8 target, highlighting PALI-2108's multi-billion dollar potential in IBD treatment.
ABVX AMGN JNJ MRK PALI
BenzingaJul 17, 2026, 6:04 PMBenzinga Newsdesk
'Biotech Abivax re-engages investment bank Centerview for Big Pharma takeover talks' - La Lettre
https://www.lalettre.fr/fr/english-corner/2026/07/17/biotech-abivax-re-engages-investment-bank-centerview-for-big-pharma-takeover-talks,110842674-gra
ABVX AZN LLY
BenzingaJul 9, 2026, 3:59 PMBenzinga Newsdesk
Piper Sandler Maintains Overweight on Abivax, Raises Price Target to $175
ABVX